Mark J. Ratain to Kinetics
This is a "connection" page, showing publications Mark J. Ratain has written about Kinetics.
Connection Strength
0.373
-
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites. Xenobiotica. 2018 Oct; 48(10):973-983.
Score: 0.123
-
A pharmacogenetic study of vorinostat glucuronidation. Pharmacogenet Genomics. 2010 Oct; 20(10):638-41.
Score: 0.075
-
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin Cancer Res. 2005 Sep 15; 11(18):6699-704.
Score: 0.053
-
Comparative Effects of CT Imaging Measurement on RECIST End Points and Tumor Growth Kinetics Modeling. Clin Transl Sci. 2016 Feb; 9(1):43-50.
Score: 0.027
-
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013; 8(1):e54522.
Score: 0.022
-
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases. Drug Metab Dispos. 2010 Jan; 38(1):32-9.
Score: 0.018
-
UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers. Pharmacogenet Genomics. 2007 Aug; 17(8):619-27.
Score: 0.015
-
Interpatient and intrapatient variability in vinblastine pharmacokinetics. Clin Pharmacol Ther. 1987 Jan; 41(1):61-7.
Score: 0.015
-
Phase I clinical and pharmacological study of thymidine (NSC 21548) and cis-diamminedichloroplatinum(II) in patients with advanced cancer. Cancer Res. 1986 Aug; 46(8):4184-8.
Score: 0.014
-
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos. 2001 May; 29(5):686-92.
Score: 0.010